These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10501918)

  • 41. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The properties and function of gamma-glutamyl hydrolase and poly-gamma-glutamate.
    Wang Y; Dias JA; Nimec Z; Rotundo R; O'Connor BM; Freisheim J; Galivan J
    Adv Enzyme Regul; 1993; 33():207-18. PubMed ID: 7689289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
    Teicher BA; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):55-62. PubMed ID: 10598556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secretion of gamma-glutamyl hydrolase in vitro.
    O'Connor BM; Rotundo RF; Nimec Z; McGuire JJ; Galivan J
    Cancer Res; 1991 Aug; 51(15):3874-81. PubMed ID: 1713122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
    Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
    Tesei A; Ricotti L; De Paola F; Amadori D; Frassineti GL; Zoli W
    Clin Cancer Res; 2002 Jan; 8(1):233-9. PubMed ID: 11801564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism-based inhibition of human folylpolyglutamate synthetase: design, synthesis, and biochemical characterization of a phosphapeptide mimic of the tetrahedral intermediate.
    Tsukamoto T; Haile WH; McGuire JJ; Coward JK
    Arch Biochem Biophys; 1998 Jul; 355(1):109-18. PubMed ID: 9647673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Folic acid antagonists pemetrexed].
    Heinzl S
    Med Monatsschr Pharm; 2004 Jul; 27(7):220-2. PubMed ID: 15296355
    [No Abstract]   [Full Text] [Related]  

  • 50. Gamma-glutamyl hydrolase and drug resistance.
    Schneider E; Ryan TJ
    Clin Chim Acta; 2006 Dec; 374(1-2):25-32. PubMed ID: 16859665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists.
    Waltham MC; Li WW; Gritsman H; Tong WP; Bertino JR
    Mol Pharmacol; 1997 May; 51(5):825-32. PubMed ID: 9145921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells.
    Chen VJ; Bewley JR; Smith PG; Andis SL; Schultz RM; Iversen PW; Tonkinson JL; Shih C
    Adv Enzyme Regul; 2000; 40():143-54. PubMed ID: 10828350
    [No Abstract]   [Full Text] [Related]  

  • 55. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
    Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study.
    John W; Picus J; Blanke CD; Clark JW; Schulman LN; Rowinsky EK; Thornton DE; Loehrer PJ
    Cancer; 2000 Apr; 88(8):1807-13. PubMed ID: 10760756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pemetrexed disodium (Eli Lilly).
    Norman P
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases.
    Sayre PH; Finer-Moore JS; Fritz TA; Biermann D; Gates SB; MacKellar WC; Patel VF; Stroud RM
    J Mol Biol; 2001 Nov; 313(4):813-29. PubMed ID: 11697906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.